Vitiligo: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• JAK 0
• PD-1 0

EU-13 is a filter, not a ranking: it only narrows the list.

No research groups match this view yet.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

  NCT06113328· Merck Sharp & Dohme LLC· Updated 10 Jul 2026

  “Business Reasons”Registry text, quoted unchanged. Source

• Terminated

  Defining the Role of the Skin Microbiome in Immune-related Adverse Events

  NCT04734704· University Hospital, Bordeaux· Updated 23 Jun 2026

  “target number of patients not reached and disabling team changes”Registry text, quoted unchanged. Source

• Terminated

  Efficacy & Tolerance of Cosmetic Product RV5098A on Face Pigmentation Maintenance in Adult Vitiligo Patients.

  NCT06446063· Pierre Fabre Dermo Cosmetique· Updated 8 May 2026

  “Lack of recruitment”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

  NCT06493578· Vyne Therapeutics Inc.· Updated 21 Apr 2026

  “Business Decision”Registry text, quoted unchanged. Source

• Withdrawn

  Evaluating the Efficacy and Safety of Metformin in Vitiligo

  NCT05607316· University of Massachusetts, Worcester· Updated 24 Sept 2024

  “Unable to secure funding.”Registry text, quoted unchanged. Source

• Suspended

  Autologous Cellular Graft in Surgical Treatment of Vitiligo

  NCT05503368· Cairo University· Updated 25 Jan 2023

  “lack of availability of the needed kits”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

  NCT06072183· Pfizer· Source

• A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

  NCT07431177· Novartis Pharmaceuticals· Source

• Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo

  NCT07920211· Teva Branded Pharmaceutical Products R&D LLC· Source

• A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo

  NCT07533019· Eli Lilly and Company· Source

• A Study of Zasocitinib in Adults With Nonsegmental Vitiligo

  NCT07108283· Takeda· Source

• Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

  NCT06855498· Incyte Corporation· Source

• A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo

  NCT06625177· Teva Branded Pharmaceutical Products R&D LLC· Source

• A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non-segmental Vitiligo

  NCT07896434· AbbVie· Source

• A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

  NCT06804811· Incyte Corporation· Source

• The Value of Methotrexate in NCES for Stable Vitiligo

  NCT07352293· Cairo University· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

See which targets of this disease your abstract mentions, and go to the people working on them.